Related Experiment Video

Updated: Aug 15, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells

Anders Wallqvist1, Ruili Huang, David G Covell

  • 1Science Applications International Corp., National Cancer Institute, NIH, Bethesda, MD, USA.

Molecular Cancer Therapeutics
|October 18, 2005
PubMed

Insights

This study links cancer cell chromosome abnormalities to drug responses, identifying novel anticancer compounds. These potential new drugs target unexplored areas, offering new avenues for cancer treatment discovery.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Cancer cell karyotypic features are often overlooked in anticancer drug development.
  • Tumor cell lines exhibit significant chromosomal aberrations, impacting drug sensitivity.

Purpose of the Study:

  • To investigate the association between cancer cell karyotypic variables and drug screening data.
  • To identify novel small-molecule anticancer agents by analyzing drug response patterns in relation to chromosomal complexity.

Main Methods:

  • Utilized the National Cancer Institute's 60 tumor cell line drug screening panel (NCI-60) data.
  • Employed a self-organizing map to analyze associations between karyotypic complexity and cytotoxic response.
  • Screened small-molecule compounds for specific links to chromosomal aberrations.

Main Results:

  • Identified a correlation between karyotypic complexity and specific cytotoxic responses.
  • Discovered thirteen distinct groups of compounds with potential anticancer activity.
  • These compounds are associated with unexplored regions of the NCI-60 drug response landscape.

Conclusions:

  • Karyotypic features can guide the discovery of novel anticancer agents.
  • The identified compounds represent potential new classes of anticancer drugs.
  • This approach may uncover new therapeutic strategies by targeting specific chromosomal profiles.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...